Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. (Q43851436)
Jump to navigation
Jump to search
scientific article published in January 2002
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. |
scientific article published in January 2002 |
Statements
1 reference
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. (English)
1 reference
Markus Sieber
1 reference
Hans Tesch
1 reference
Beate Pfistner
1 reference
Ulrich Rueffer
1 reference
Bernd Lathan
1 reference
Oana Brosteanu
1 reference
Ursula Paulus
1 reference
Tina Koch
1 reference
Markus Loeffler
1 reference
Andreas Engert
1 reference
Andreas Josting
1 reference
Jürgen Wolf
1 reference
Dirk Hasenclever
1 reference
Jeremy Franklin
1 reference
Eckhart Duehmke
1 reference
Axel Georgii
1 reference
Klaus-Peter Schalk
1 reference
Hartmut Kirchner
1 reference
Gottfried Doelken
1 reference
Reinhold Munker
1 reference
Peter Koch
1 reference
Richard Herrmann
1 reference
Richard Greil
1 reference
Anna Paola Anselmo
1 reference
Volker Diehl
1 reference
1 January 2002
1 reference
1 reference
20
1 reference
2
1 reference
476-484
1 reference
Identifiers
1 reference
1 reference